R&G Pharma released its performance for the first three quarters, with a net profit attributable to the parent company of 95.5668 million yuan, an increase of 13.21%
I'm PortAI, I can summarize articles.
According to the Zhitong Finance APP, R&G Pharma released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 607 million yuan, a year-on-year increase of 8.09%. The net profit attributable to shareholders of the listed company was 95.5668 million yuan, a year-on-year increase of 13.21%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 81.3334 million yuan, a year-on-year increase of 22.47%. The basic earnings per share were 1 yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments